(The Center Square) - The U.S. Supreme Court, in a unanimous decision on Thursday, ruled that a cardiovascular drugmaker did not violate America's patent laws. The ruling could allow for generic drug manufacturers to produce more without fear of patent lawsuits. 

Justices on the high court ruled in favor of Hikma Pharmaceuticals in a case over whether it infringed on Amarin Pharma's cardiovascular medication, Vascepa. The justices said Hikma Pharmaceuticals did not infringe on Amarin's patent. 

 

Originally published on thecentersquare.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.